Trials / Withdrawn
WithdrawnNCT00472771
INNO-206 in Patients With Small Cell Lung Cancer (SCLC)
A Phase II, Open-label Study of INNO-206 in Patients With Recurrent Extensive Small Cell Lung Cancer After First-line Platinum-based Therapy
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- CytRx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether INNO-206 is effective in the treatment of small cell lung cancer.
Detailed description
This is a phase II, open-label, prospective, multicenter, single-arm study of INNO 206 in adult patients with recurrent extensive small cell lung cancer sensitive to first-line platinum-based therapy. The primary objective of the study is to determine the objective overall response rate. Secondary objectives include evaluating the treatment-related toxicities in this patient population and determining the pharmacokinetic (PK) profile of INNO-206 in a minimum of 12 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INNO-206 |
Timeline
- Start date
- 2008-05-01
- Completion
- 2008-11-01
- First posted
- 2007-05-14
- Last updated
- 2012-02-09
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00472771. Inclusion in this directory is not an endorsement.